Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs

Circulation Journal

Volumn 71, Issue 8, 2007, Pages 1250-1257

  Miyaji, Kohei ^b   Tada, Hiroshi ^a,c   Kusano, Kengo Fukushima ^b   Hashimoto, Tohru ^a   Kaseno, Kenichi ^a   Hiramatsu, Shigeki ^a   Tadokoro, Kazuyoshi ^a   Naito, Shigeto ^a   Nakamura, Kazufumi ^b   Oshima, Shigeru ^a   Taniguchi, Koichi ^a   Ohe, Tohru ^b  

^a GUNMA PREFECTURAL CARDIOVASCULAR CENTER   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Bepridil

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; APRINDINE; BEPRIDIL; CIBENZOLINE; DISOPYRAMIDE; FLECAINIDE; PILSICAINIDE; PIRMENOL; WARFARIN;

ADULT; AGED; ARTICLE; CARDIOVERSION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; QT PROLONGATION; SINUS RHYTHM; TORSADE DES POINTES;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BEPRIDIL; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; SALVAGE THERAPY; TORSADES DE POINTES; TREATMENT OUTCOME;

EID: 34547575590     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.1250     Document Type: Article

References (31)

1. Miller JM, Zipes DP. Management of the patient with cardiac arrhythmia. In: Braunwald E, Zipes DP, Libby P, editors. Heart disease, 6th edn. Philadelphia: Saunders; 2001; 700-774.
2. Stroobandt R, Stiels B, Hoebrechts R, on behalf of the Propafenone Atrial Fibrillation Trial Investigators. Propafenone for conversion and prophylaxis of atrial fibrillation. Am J Cardiol 1997; 79: 418-423.
3. Naccarelli GV, Dorian P, Hohnloser SH, Coumel P. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter: The Flecainide Multicenter Atrial Fibrillation Study Group. Am J Cardiol 1996; 77: 53A-59A.
4. Kuhlkamp V, Schmid F, Risler T, Seipel L. Randomized comparison of flecainide and cibenzoline in the conversion of atrial fibrillation. Int J Cardiol 1991; 31: 65-69.
5. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials. Circulation 1990; 82: 1106-1116.
6. Nichol G, McAlister F, Pham B, Laupacis A, Shea B, Green M, et al. Meta-analysis of randomized controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart 2002; 87: 535-543.
7. Steinbeck G, Remp T, Hoffmann E. Effects of Class I drugs on atrial fibrillation. J Cardiovasc Electrophysiol 1998; 9: S104-S108.
8. Komatsu T, Sato Y, Tachibana H, Nakamura M, Horiuchi D, Okumura K. Randomized crossover study of the long-term effects of pilsicainide and cibenzoline in preventing recurrence of symptomatic paroxysmal atrial fibrillation: Influence of the duration of arrhythmia before therapy. Circ J 2006; 70: 667-672.
9. 2+-dependent action potentials in vascular muscle of dog coronary artery. J Cardiovasc Pharmacol 1981; 3: 906-914.
10. DiBianco R, Alpert J, Katz RJ, Spann J, Chesler E, Ferri DP, et al. Bepridil for chronic stable angina pectoris: Results of a prospective multi-center, placebo controlled, dose-ranging study in 77 patients. Am J Cardiol 1984; 53: 35-41.
11. Anno T, Furuta T, Itoh M, Kodma I, Toyama J, Yamada K. Effects of bepridil on the electrophysiological properties of guinea-pig ventricular muscles. Br J Pharmacol 1984; 81: 41-47.
12. + currents, Ikr and Iks, in guinea-pig ventricular myocytes. Br J Pharmacol 1999; 128: 1733-1738.
13. Kato R, Singh BN. Effects of bepridil on the electrophysiological properties of isolated canine and rabbit myocardial fibers. Am Heart J 1986; 111: 271-279.
14. Yoshida T, Niwano S, Inuo K, Saito J, Kojima J, Murakami K, et al. Bepridil prevents paroxysmal atrial fibrillation by a class III anti-arrhythmic drug effect. Pacing Clin Electrophysiol 2003; 26: 314-317.
15. Yoshida T, Niwano S, Inuo K, Saito J, Kojima J, Ikeda K, et al. Evaluation of the effect of bepridil on paroxysmal atrial fibrillation. Circ J 2003; 67: 11-15.
16. Fujiki A, Tsuneda T, Sugao M, Mizumaki K, Inoue H. Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. Am J Cardiol 2003; 92: 472-475.
17. Nakazato Y, Yasuda M, Sasaki A, Iida Y, Kawano Y, Nakazato K, et al. Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ J 2005; 69: 44-48.
18. Perelman MS, McKenna WJ, Rowland E, Krikler DM. A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation. Br Heart J 1987; 58: 339-344.
19. Yasuda M, Nakazato Y, Sasaki A, Kawano Y, Nakazato K, Tokano T, et al. Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. Circ J 2006; 70: 662-666.
20. Tada H, Naito S, Kurosaki K, Ueda M, Ito S, Shinbo G, et al. Segmental pulmonary vein isolation for paroxysmal atrial fibrillation improves quality of life and clinical outcomes. Circ J 2003; 67: 861-865.
21. Bazette HC. An analysis of time relations of electrocardiograms. Heart 1920; 7: 353-367.
22. The Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84: 1831-1851.
23. Kodama I, Ogawa S, Inoue H, Kasanuki H, Kato T, Mitamura H, et al. Profiles of aprindine, cibenzoline, pilsicainide and pirmenol in the framework of the Sicilian Gambit. Jpn Circ J 1999; 63: 1-12.
24. Kobayashi S, Reien Y, Ogura T, Saito T, Masuda Y, Nakaya H. Inhibitory effect of bepridil on hKv1.5 channel current: Comparison with amiodarone and E-4031. Eur J Pharmacol 2001; 430: 149-157.
25. Courtemanche M, Ramirez RJ, Nattel S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: Insight from a mathematical model. Cardiovasc Res 1999; 42: 477-489.
26. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997; 81: 512-525.
27. Kaori S, A Shiroshita-Takeshita, Gernot S, Stanley N. Effects of Anti-arrhythmic drugs on fibrillation in the remodeled atrium: Insights into the mechanism of the superior efficacy of amiodarone. Circulation 2003; 107: 1440-1446.
28. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342: 913-920.
29. Sato D, Niwano S, Imaki R, Masaki Y, Sasaki S, Yuge M, et al. Bepridil inhibits sub-acute phase of atrial electrical remodeling in canine rapid atrial stimulation model. Circ J 2006; 70: 206-213.
30. Komatsu T, Tachibana H, Sato Y, Ozawa M, Nakamura M, Okumura K. Efficacy of amiodarone for preventing the recurrence of symptomatic paroxysmal and persistent atrial fibrillation after cardioversion. Circ J 2007; 71: 46-51.
31. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmia in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89: 224-227.